TheStreet's Jim Cramer says many people felt Mannkind's inhaled insulin drug Afrezza would fail and as a result, 28-percent of the float was short and any good news would get the stock going. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock since Mannkind has already spent a "fortune" developing Afrezza. However, Cramer says he is completely neutral and sometimes it's better to admit you don't know where something is going.

At the time of publication, Cramer was long ___.

More from Video

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

This Could Be the Summer of Hard Seltzer

This Could Be the Summer of Hard Seltzer